WO2011002422A3 - Solubility enhancing pharmaceutical formulation - Google Patents

Solubility enhancing pharmaceutical formulation Download PDF

Info

Publication number
WO2011002422A3
WO2011002422A3 PCT/TR2010/000123 TR2010000123W WO2011002422A3 WO 2011002422 A3 WO2011002422 A3 WO 2011002422A3 TR 2010000123 W TR2010000123 W TR 2010000123W WO 2011002422 A3 WO2011002422 A3 WO 2011002422A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulation
solubility enhancing
enhancing pharmaceutical
active substance
therapeutically active
Prior art date
Application number
PCT/TR2010/000123
Other languages
French (fr)
Other versions
WO2011002422A2 (en
Inventor
Bilgic Mahmut
Original Assignee
Bilgic Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bilgic Mahmut filed Critical Bilgic Mahmut
Priority to EP10763477A priority Critical patent/EP2448564A2/en
Publication of WO2011002422A2 publication Critical patent/WO2011002422A2/en
Publication of WO2011002422A3 publication Critical patent/WO2011002422A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Abstract

The present invention relates to the pharmaceutical formulations comprising the therapeutically active substance ezetimibe with solubility problem in combination with the therapeutically active substance astorvastatin, and the methods for the preparation thereof, and the use thereof.
PCT/TR2010/000123 2009-07-02 2010-06-25 Solubility enhancing pharmaceutical formulation WO2011002422A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10763477A EP2448564A2 (en) 2009-07-02 2010-06-25 Solubility enhancing pharmaceutical formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR200905149 2009-07-02
TR2009/05149 2009-07-02

Publications (2)

Publication Number Publication Date
WO2011002422A2 WO2011002422A2 (en) 2011-01-06
WO2011002422A3 true WO2011002422A3 (en) 2011-04-28

Family

ID=43411648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2010/000123 WO2011002422A2 (en) 2009-07-02 2010-06-25 Solubility enhancing pharmaceutical formulation

Country Status (2)

Country Link
EP (1) EP2448564A2 (en)
WO (1) WO2011002422A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013006332A (en) * 2013-06-05 2014-12-19 Alparis Sa De Cv Oral pharmaceutical compositions for use in dyslipidemias.
CN103340852A (en) * 2013-07-01 2013-10-09 北京阜康仁生物制药科技有限公司 Pharmaceutical composition containing ezetimibe and atorvastatin
CN103784436B (en) * 2014-02-27 2016-06-01 安徽联创生物医药股份有限公司 A kind of blood fat-decreasing compound preparation and its preparation method
CN104013617A (en) * 2014-05-13 2014-09-03 万特制药(海南)有限公司 Composition containing ezetimibe and atorvastatin calcium and preparation method of composition
TR201702101A2 (en) * 2017-02-13 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi ATORVASTATIN CALCIUM AND EZETIMIBIN PHARMACEUTICAL TWO-LAYER TABLET COMPOSITION
TR201820324A2 (en) * 2018-12-25 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi ATORVASTATIN CALCIUM AND EZETİMİBİN PHARMACEUTICAL DOUBLE LAYER TABLET FORMULATION
KR102496243B1 (en) * 2020-01-14 2023-02-07 일동제약(주) A tablet comprising atorvastatin and ezetimibe
EP4188338A1 (en) 2020-07-27 2023-06-07 KRKA, d.d., Novo mesto Bilayer tablet comprising ezetimibe and atorvastatin

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010993A1 (en) * 2002-07-26 2004-02-05 Merck Sharp & Dohme Limited Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
WO2007003365A1 (en) * 2005-07-06 2007-01-11 Krka Pharmaceutical composition comprising simvastatin and ezetimibe
WO2008101723A2 (en) * 2007-02-23 2008-08-28 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2010021608A1 (en) * 2008-08-22 2010-02-25 Mahmut Bilgic Solubility enhancing pharmaceutical formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AR035533A1 (en) 2001-01-26 2004-06-02 Schering Corp USE OF AT LEAST AN INHIBITOR OF THE ABSORPTION OF THE STEROLS OR THEIR SALTS, SOLVATOS, PHARMACEUTICALLY ACCEPTABLE DRUGS OR MIXTURES OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF SITOSTEROLEMIA, COMPOSITIONS OF THE PHARMACEUTICAL USE
US20070112050A1 (en) 2005-04-12 2007-05-17 Psivida Inc. HMGCoA reductase inhibitor combinations and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010993A1 (en) * 2002-07-26 2004-02-05 Merck Sharp & Dohme Limited Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
WO2007003365A1 (en) * 2005-07-06 2007-01-11 Krka Pharmaceutical composition comprising simvastatin and ezetimibe
WO2008101723A2 (en) * 2007-02-23 2008-08-28 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2010021608A1 (en) * 2008-08-22 2010-02-25 Mahmut Bilgic Solubility enhancing pharmaceutical formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GAGNE C ET AL: "EFFICACY AND SAFETY OF EZETIMIBE COADMINISTERED WITH ATORVASTATIN OR SIMVASTATIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 105, no. 21, 28 May 2002 (2002-05-28), pages 2469 - 2475, XP001132086, ISSN: 0009-7322, DOI: DOI:10.1161/01.CIR.0000018744.58460.62 *

Also Published As

Publication number Publication date
EP2448564A2 (en) 2012-05-09
WO2011002422A2 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
WO2010021607A3 (en) Pharmaceutical formulation
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
WO2012055567A3 (en) Use of malononitrilamides in neuropathic pain
WO2010030598A3 (en) Pharmaceutical formulations comprising pemetrexed
WO2011093824A3 (en) Effervescent formulations comprising cefaclor
WO2012021715A3 (en) Stable formulations of linaclotide
EP2130552A4 (en) Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
IL206952A (en) Aminodihydrothiazine derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
IL221952A (en) 2,3-dihydro-1h-inden-1-yl-2,7- diazaspiro[3.5] nonane derivatives and pharmaceutical compositions comprising the same
ZA201101477B (en) Co-crystals and pharmaceutical formulations comprising the same
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
IL218490A (en) Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, compositions comprising the same and use thereof in the preparation of pharmaceutical compositions
EP2379079A4 (en) Pharmaceutical formulations comprising voriconazole and processes for preparation thereof
PL2081547T3 (en) Galenic form for the trans-mucosal delivery of active ingredients
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2011019326A3 (en) Solubility and stability enchancing pharmaceutical formulation
IL208370A0 (en) Improved formulations for poorly permeable active pharmaceutical ingredients
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2010072958A3 (en) Topical pharmaceutical composition containing a water-sensitive active principle
WO2009135593A3 (en) Solid pharmaceutical formulation with delayed release
EP2045253A4 (en) alpha-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
WO2011144674A3 (en) PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
WO2011076842A3 (en) Aerosol formulation for copd
EP2241569A4 (en) Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10763477

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010763477

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010763477

Country of ref document: EP